Protease transition state inhibitor prodrugs
US11033600B2 · kind B2 · utility
16Cited by
2References
19Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 28, 2017 |
| Grant date | Jun 15, 2021 |
| Priority date | — |
| Expiry date | Aug 9, 2037 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are protease transition state inhibitor/analogue prodrug compounds selected from the group consisting of esters, carbamates, ester phosphates, and pharmaceutically acceptable salts thereof. Compositions containing such prodrugs are also disclosed, along with methods of using such compounds therapeutically or prophylactically against calicivirus, picornavirus, and/or coronavirus infection, as well as other conditions, such as malaria, cancer, stroke, heart attack, neural degeneration, cataracts, and glaucoma through inhibition of the variety of proteases associated with progression of such conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.